Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model

McCormick, 2002, Lassa fever, Curr Top Microbiol Immunol, 262, 75, 10.1007/978-3-642-56029-3_4 Salvato, 2009, Vaccines against Lassa fever Moraz, 2011, Pathogenesis of arenavirus hemorrhagic fevers, Expert Rev Anti-infect Ther, 9, 49, 10.1586/eri.10.142 Droniou-Bonzom, 2011, Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP, J Virol, 10.1128/JVI.05616-11 Salvato, 2005, Arenaviridae, 715 Oldstone, 2002, Biology and pathogenesis of lymphocytic choriomeningitis virus infection, Curr Top Microbiol Immunol, 263, 83, 10.1007/978-3-642-56055-2_6 Grant-Klein, 2011, Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses, Antivir Res, 162, 148 Khan, 2008, New opportunities for field research on the pathogenesis and treatment of Lassa fever, Antiviral Res, 78, 103, 10.1016/j.antiviral.2007.11.003 Fichet-Calvet, 2009, Risk maps of Lassa fever in West Africa, PLoS Negl Trop Dis, 3, 10.1371/journal.pntd.0000388 Loureiro, 2011, Molecular determinants of Arenavirus Z protein homo-oligomerization and L polymerase binding, J Virol, 10.1128/JVI.05691-11 Richmond, 2003, Lassa fever: epidemiology, clinical features, and social consequences, BMJ, 327, 1271, 10.1136/bmj.327.7426.1271 Paweska, 2009, Nosocomial outbreak of novel arenavirus infection, southern Africa, Emerg Infect Dis, 15, 1598, 10.3201/eid1510.090211 Briese, 2009, Genetic detection and characterization of lujo virus, a new hemorrhagic fever-associated arenavirus from Southern Africa, PLoS Pathog, 4, e1000455, 10.1371/journal.ppat.1000455 Ishii, 2011, Novel arenavirus Zambia, Emerg Infect Dis, 17, 1921, 10.3201/eid1710.10452 Cummins, 1990, Acute sensorineural deafness in Lassa fever, JAMA, 264, 2093, 10.1001/jama.1990.03450160063030 Liao, 1992, Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause, Otolaryngol Head Neck Surg, 106, 226, 10.1177/019459989210600303 Macher, 2006, Historical Lassa fevers reports and 30-year clinical update, Emerg Infect Dis, 12, 835, 10.3201/eid1205.050052 Neuman, 2011, Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors, Antimicrob Agents Chemother, 55, 4631, 10.1128/AAC.00650-11 Borio, 2002, Hemorrhagic fever viruses as biological weapons: medical and public health management, JAMA, 287, 2391, 10.1001/jama.287.18.2391 Cuevas, 2011, Junin virus infects mouse cells and induces innate immune responses, J Virol, 85, 11058, 10.1128/JVI.05304-11 Peters, 1987, Experimental studies of arenaviral hemorrhagic fevers, Curr Top Microbiol Immunol, 134, 5, 10.1007/978-3-642-71726-0_2 Gowen, 2008, Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses, Antivir Res, 78, 79, 10.1016/j.antiviral.2007.10.002 Lukashevich, 2010, Pathogenesis of Lassa virus infection in experimental animals, 101 Carrion, 2007, Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues, J Virol, 81, 6482, 10.1128/JVI.02876-06 Baize, 2009, Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys, J Virol, 83, 5890, 10.1128/JVI.01948-08 Sbrana, 2006, Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with pirital virus (arenaviridae): a rodent model of Lassa fever, Am J Trop Med Hyg, 74, 1096, 10.4269/ajtmh.2006.74.1096 Zapata, 2011, Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever, Antivir Res, 92, 125, 10.1016/j.antiviral.2011.07.015 Lukashevich, 1992, Generation of reassortants between African arenaviruses, Virology, 188, 600, 10.1016/0042-6822(92)90514-P Lukashevich, 2005, A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses, J Virol, 79, 13934, 10.1128/JVI.79.22.13934-13942.2005 Lukashevich, 2008, Safety, immunogenicity, and efficacy of the ML29 vaccine for Lassa fever in small non-human primates, Vaccine, 26, 5246, 10.1016/j.vaccine.2008.07.057 Lukashevich, 2010, A live reassortant vaccine for Lassa fever Lukashevich, 1985, Lassa virus lethality for inbred mice, Ann Soc Belg Med Trop, 65, 207 Pushko, 2001, Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses, J Virol, 75, 11677, 10.1128/JVI.75.23.11677-11685.2001 Lukashevich, 2004, LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration, Arch Virol, 149, 2319, 10.1007/s00705-004-0385-9 Lukashevich, 1993, Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen, J Med Virol, 40, 210, 10.1002/jmv.1890400308 Jiang, 2011, Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs, Vaccine, 29, 1248, 10.1016/j.vaccine.2010.11.079 Barber, 2003, Cutting edge: rapid in vivo killing by memory CD8 T cells, J Immunol, 171, 27, 10.4049/jimmunol.171.1.27 La Posta, 1993, Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus, J Virol, 67, 3497, 10.1128/JVI.67.6.3497-3506.1993 Barkar, 1989, Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections, Vopr Virusol, 34, 598 McIntyre, 1985, Exquisite specificity of adoptive immunization in arenavirus-infected mice, Antivir Res, 5, 299, 10.1016/0166-3542(85)90044-0 McCormick, 1986, Lassa fever, effective therapy with ribavirin, N Engl J Med, 314, 20, 10.1056/NEJM198601023140104 Botten, 2006, Identification of protective Lassa virus epitopes that are restricted by HLA-A2, J Virol, 80, 8351, 10.1128/JVI.00896-06 Boesen, 2005, Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2. 1 Transgenic Mice, Clin Diagn Lab Immunol, 12, 1223, 10.1128/CDLI.12.10.1223-1230.2005 Meulen, 2004, Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones, Virology, 321, 134, 10.1016/j.virol.2003.12.013 Kotturi, 2011, Human CD8+ and CD4+ T cell memory to lymphocytic choriomeningitis virus infection, J Virol, 85, 11770, 10.1128/JVI.05477-11 Hastie, 2011, Crystal structure of the Lassa virus nucleoprotein–RNA complex reveals a gating mechanism for RNA binding Flatz, 2010, T cell-dependence of Lassa fever pathogenesis, PLoS Pathogen, 6, e1000836, 10.1371/journal.ppat.1000836 Zhou, 2005, MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection, Eur J Immunol, 35, 822, 10.1002/eji.200425730 Zhou, 2010, Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus, J Virol, 84, 9452, 10.1128/JVI.00155-10 Zhou, 2009, MyD88 intrinsically regulates CD4 T-cell responses, J Virol, 83, 1625, 10.1128/JVI.01770-08 Jung, 2008, Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88, J Virol, 82, 196, 10.1128/JVI.01640-07 Zhou, 2008, Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses, J Neuroimmunol, 194, 70, 10.1016/j.jneuroim.2007.11.018